GB201209244D0 - Compositions - Google Patents

Compositions

Info

Publication number
GB201209244D0
GB201209244D0 GB201209244A GB201209244A GB201209244D0 GB 201209244 D0 GB201209244 D0 GB 201209244D0 GB 201209244 A GB201209244 A GB 201209244A GB 201209244 A GB201209244 A GB 201209244A GB 201209244 D0 GB201209244 D0 GB 201209244D0
Authority
GB
United Kingdom
Prior art keywords
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB201209244A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GLOBALACORN Ltd
Original Assignee
GLOBALACORN Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GLOBALACORN Ltd filed Critical GLOBALACORN Ltd
Priority to GB201209244A priority Critical patent/GB201209244D0/en
Publication of GB201209244D0 publication Critical patent/GB201209244D0/en
Priority to CA2913313A priority patent/CA2913313A1/en
Priority to EP13725462.9A priority patent/EP2854821A1/en
Priority to US14/403,560 priority patent/US20150119352A1/en
Priority to PCT/GB2013/051377 priority patent/WO2013175231A1/en
Priority to AU2013264966A priority patent/AU2013264966A1/en
Priority to HK15103596.5A priority patent/HK1203054A1/xx
Priority to JP2015513277A priority patent/JP2015517565A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
GB201209244A 2012-05-25 2012-05-25 Compositions Ceased GB201209244D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GB201209244A GB201209244D0 (en) 2012-05-25 2012-05-25 Compositions
CA2913313A CA2913313A1 (en) 2012-05-25 2013-05-24 Dinuceloside polyphosphates for the treatment of pain
EP13725462.9A EP2854821A1 (en) 2012-05-25 2013-05-24 Dinuceloside polyphosphates for the treatment of pain
US14/403,560 US20150119352A1 (en) 2012-05-25 2013-05-24 Dinuceloside polyphosphates for the treatment of pain
PCT/GB2013/051377 WO2013175231A1 (en) 2012-05-25 2013-05-24 Dinuceloside polyphosphates for the treatment of pain
AU2013264966A AU2013264966A1 (en) 2012-05-25 2013-05-24 Dinuceloside polyphosphates for the treatment of pain
HK15103596.5A HK1203054A1 (en) 2012-05-25 2013-05-24 Dinuceloside polyphosphates for the treatment of pain
JP2015513277A JP2015517565A (ja) 2012-05-25 2013-05-24 疼痛の治療のためのジヌクレオシドポリリン酸

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201209244A GB201209244D0 (en) 2012-05-25 2012-05-25 Compositions

Publications (1)

Publication Number Publication Date
GB201209244D0 true GB201209244D0 (en) 2012-07-04

Family

ID=46546668

Family Applications (1)

Application Number Title Priority Date Filing Date
GB201209244A Ceased GB201209244D0 (en) 2012-05-25 2012-05-25 Compositions

Country Status (8)

Country Link
US (1) US20150119352A1 (enExample)
EP (1) EP2854821A1 (enExample)
JP (1) JP2015517565A (enExample)
AU (1) AU2013264966A1 (enExample)
CA (1) CA2913313A1 (enExample)
GB (1) GB201209244D0 (enExample)
HK (1) HK1203054A1 (enExample)
WO (1) WO2013175231A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
GB201320962D0 (en) * 2013-11-27 2014-01-08 Globalacorn Ltd Compositions
WO2017209267A1 (ja) * 2016-06-03 2017-12-07 塩野義製薬株式会社 プリン誘導体
CN112004551A (zh) 2018-03-15 2020-11-27 丹米尔治疗有限责任公司 3”,5”-二烷氧基苯甲酰基-3’-氨基-3’-脱氧腺苷-5’-三磷酸及其药物用途
US20230000063A1 (en) * 2019-12-13 2023-01-05 Chugai Seiyaku Kabushiki Kaisha System for detecting extracellular purinergic receptor ligand, and non-human animal having the system introduced thereinto
US20230032473A1 (en) * 2021-07-23 2023-02-02 Wisconsin Alumni Research Foundation Nad(h) nanoparticles and methods of use
CN114685588B (zh) * 2022-05-05 2024-03-29 江苏申基生物科技有限公司 一种含开环核苷结构的起始加帽寡核苷酸引物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5049550A (en) * 1987-11-05 1991-09-17 Worcester Foundation For Experimental Biology Diadenosine 5', 5'"-p1, p4,-tetraphosphate analogs as antithrombotic agents
JP2783880B2 (ja) * 1989-11-24 1998-08-06 富士レビオ株式会社 心臓病治療剤
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US5837861A (en) * 1997-02-10 1998-11-17 Inspire Pharmaceuticals, Inc. Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency
US5681823A (en) * 1996-05-02 1997-10-28 Prp Inc. P1, P4 -dithio-P2 -P3 -monochloromethylene 5', 5'"-diadenosine P1, P4 -tetraphosphate as antithrombotic agent
US6462028B2 (en) * 1997-07-25 2002-10-08 Inspire Pharmaceuticals, Inc. Method of promoting cervical and vaginal secretions
GB2394419B (en) * 2001-06-25 2005-09-07 Inspire Pharmaceuticals Inc Joint lubrication with p2y purinergic receptor agonists
CN1612739A (zh) * 2001-11-06 2005-05-04 印斯拜尔药品股份有限公司 治疗或预防炎性疾病的方法
EP1348466A3 (en) * 2002-02-01 2003-10-29 Inspire Pharmaceuticals, Inc. Method for treating pain with adenosine-tetraphosphates
FR2842424A1 (fr) * 2002-07-22 2004-01-23 Univ Paris 7 Denis Diderot Utilisation du nad ou de l'un de ses analogues, substrat des mono-adp-ribosyl tranferases, pour la preparation d'un medicament destine au traitement des pathologies liees aux recepteurs purinergiques
GB0502250D0 (en) * 2005-02-03 2005-03-09 Ic Vec Ltd Use

Also Published As

Publication number Publication date
HK1203054A1 (en) 2015-10-16
CA2913313A1 (en) 2013-11-28
AU2013264966A1 (en) 2015-01-22
US20150119352A1 (en) 2015-04-30
WO2013175231A1 (en) 2013-11-28
EP2854821A1 (en) 2015-04-08
JP2015517565A (ja) 2015-06-22

Similar Documents

Publication Publication Date Title
GB201200707D0 (en) Composition
IL233649A0 (en) Preparations derived from chitosan
GB2511197B (en) Compositions
GB201210800D0 (en) Compositions
GB201209244D0 (en) Compositions
ZA201503157B (en) Compositions
GB201201287D0 (en) Compositions
GB201206035D0 (en) Composition
EP2910537A4 (en) AGENT COMPOSITION GENERATING GAS
GB201208133D0 (en) Composition
ZA201503062B (en) Compositions
GB201220068D0 (en) Compositions
ZA201502542B (en) Compositions
ZA201406753B (en) Long acting compositions
GB201219973D0 (en) Compositions
GB201219962D0 (en) Compositions
GB201219980D0 (en) Compositions
TWI561248B (en) Peracid-generating compositions
EP2926813A4 (en) METFORMIN-Orlistat COMPOSITIONS
GB201223148D0 (en) Compositions
GB201222702D0 (en) Compositions
GB201218959D0 (en) Compositions
GB201209187D0 (en) Compositions
GB201209189D0 (en) Compositions
GB201204103D0 (en) Compositions

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)